Federal Register / Vol. 86, No. 31 / Thursday, February 18, 2021 / Notices 10093 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this notice to Kyverna 

Therapeutics (‘‘Kyverna’’) located in 

Berkeley, CA. 

DATES: Only written comments and/or 

complete applications for a license 

which are received by the National 

Cancer Institute’s Technology Transfer 

Center on or before March 5, 2021 will 

be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an Exclusive Patent License should be 

directed to: David A Lambertson, Ph.D., 

Senior Technology Transfer Manager, 

NCI Technology Transfer Center at 

(240)-276–5530 or Email: 

david.lambertson@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

The following represents the 

intellectual property to be licensed 

under the prospective agreement: 

(A) U.S. Provisional Patent 

Application 62/006, 313 entitled 

‘‘Chimeric Antigen Receptors Targeting 

CD–19’’ [HHS Ref. E–042–2014–0–US– 

01], PCT Patent Application PCT/ 

US2015/033473 entitled ‘‘Chimeric 

Antigen Receptors Targeting CD–19’’ 

[HHS Ref. E–042–2014–0–PCT–02], 

Australian Patent 2015270912 entitled 

‘‘Chimeric Antigen Receptors Targeting 

CD–19’’ [HHS Ref. E–042–2014–0–AU– 

03], Canadian Patent Application 

2951045 entitled ‘‘Chimeric Antigen 

Receptors Targeting CD–19’’ [HHS Ref. 

E–042–2014–0–CA–04], Chinese Patent 

Application 201580033802.5 entitled 

‘‘Chimeric Antigen Receptors Targeting 

CD–19’’ [HHS Ref. E–042–2014–0–CN– 

05], European Patent 3149044 entitled 

‘‘Chimeric Antigen Receptors Targeting 

CD–19’’ [HHS Ref. E–042–2014–0–EP– 

06] (validated in Germany [HHS Ref. E– 

042–2014–0–DE–19], Spain [HHS Ref. 

E–042–2014–0–ES–20], France [HHS 

Ref. E–042–2014–0–FR–21], the United 

Kingdom [HHS Ref. E–042–2014–0–GB– 

22], Italy [HHS Ref. E–042–2014–0–IT– 

23], and Ireland [HHS Ref. E–042–2014– 

0–IE–24], and lodged in Hong Kong [E– 

042–2014–0–HK–16]), Israeli Patent 

Application 249305 entitled ‘‘Chimeric 

Antigen Receptors Targeting CD–19’’ 

[HHS Ref. E–042–2014–0–IL–07], Indian 

Patent Application 291647041047 

entitled ‘‘Chimeric Antigen Receptors 

Targeting CD–19’’ [HHS Ref. E–042– 

2014–0–IN–08], Japanese Patent 

Application 2016–571017 entitled 

‘‘Chimeric Antigen Receptors Targeting 

CD–19’’ [HHS Ref. E–042–2014–0–JP– 

09], South Korean Patent Application 

2016–7036828 entitled ‘‘Chimeric 

Antigen Receptors Targeting CD–19’’ 

[HHS Ref. E–042–2014–0–KR–10], 

Mexican Patent Application MX/a/ 

2016/015834 entitled ‘‘Chimeric 

Antigen Receptors Targeting CD–19’’ 

[HHS Ref. E–042–2014–0–MX–11], New 

Zealand Patent Application 727167 

entitled ‘‘Chimeric Antigen Receptors 

Targeting CD–19’’ [HHS Ref. E–042– 

2014–0–NZ–12], Saudi Arabian Patent 

Application 516380406 entitled 

‘‘Chimeric Antigen Receptors Targeting 

CD–19’’ [HHS Ref. E–042–2014–0–SA– 

13], Singaporean Patent Application 

11201609960Q entitled ‘‘Chimeric 

Antigen Receptors Targeting CD–19’’ 

[HHS Ref. E–042–2014–0–SG–14], 

United States Patent 10,287,350 entitled 

‘‘Chimeric Antigen Receptors Targeting 

CD–19’’ [HHS Ref. E–042–2014–0–US– 

15], United States Patent Application 

16/360,281 entitled ‘‘Chimeric Antigen 

Receptors Targeting CD–19’’ [HHS Ref. 

E–042–2014–0–US–17], New Zealand 

Patent Application 764530 entitled 

‘‘Chimeric Antigen Receptors Targeting 

CD–19’’ [HHS Ref. E–042–2014–0–NZ– 

18], European Patent Application 

20197459.9 entitled ‘‘Chimeric Antigen 

Receptors Targeting CD–19’’ [HHS Ref. 

E–042–2014–0–EP–25], Australian 

Patent Application 2020267211 entitled 

‘‘Chimeric Antigen Receptors Targeting 

CD–19’’ [HHS Ref. E–042–2014–0–AU– 

26], and Japanese Patent Application 

XXX entitled ‘‘Chimeric Antigen 

Receptors Targeting CD–19’’ [HHS Ref. 

E–042–2014–0–JP–27], and all 

continuing U.S. and foreign patents/ 

patent applications for the technology 

family. 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide and the 

field of use may be limited to the 

following: 

‘‘The development, production and 

commercialization of an anti-CD19 targeting 

chimeric antigen receptor (CAR)-based 

immunotherapy using CRISPR/Cas9-edited 

allogeneic (where donor and recipient are 

different) T lymphocytes, wherein the CAR 

expresses at least: 

(1) The complementary determining region 

(CDR) sequences of the anti-CD19 antibody 

known as Hu19; 

(2) a CD8a hinge and transmembrane 

domain*; 

(3) and a CD28z T cell signaling domain*; 

for the treatment of autoimmune diseases.’’ 

This technology discloses the 

development of chimeric antigen 

receptors that recognize the CD19 cell 

surface protein. CD19 is expressed on 

the cell surface of several autoimmune 

disease cells, including lupus nephritis. 

For many autoimmune diseases there 

are no FDA-approved therapies, 

underscoring that there is an unmet 

need. The development of an 

autoimmune disease therapeutic 

targeting CD19 will benefit public 

health by providing a treatment for 

patients who may not have any options. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a completed license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: February 4, 2021. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2021–03221 Filed 2–17–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Amended Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Institute of 

General Medical Sciences Special 

Emphasis Panel, March 23, 2021, 09:30 

a.m. to March 23, 2021, 05:30 p.m., 

National Institutes of Health, Natcher 

Building, 45 Center Drive, Bethesda, 

MD, 20892 which was published in the 


jbell on DSKJLSW7X2PROD with NOTICES
10094 Federal Register / Vol. 86, No. 31 / Thursday, February 18, 2021 / Notices 

Federal Register on February 04, 2021, 

86 FR 8211. 

The meeting notice is amended to 

change the date of the meeting from 

March 19, 2021 to March 23, 2021. The 

meeting is closed to the public. 

Dated: February 11, 2021. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–03188 Filed 2–17–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of General Medical 

Sciences; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: NIGMS Initial Review 

Group Training and Workforce Development 

Subcommittee—B Review of Predoctoral 

Training Grant Applications. 

Date: February 25–26, 2021. 

Time: 9:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, Bethesda, 

MD 20892 (Video Meeting). 

Contact Person: Lisa A. Newman, SCD, 

Scientific Review Officer, Office of Scientific 

Review, National Institutes of General 

Medical Sciences, National Institutes of 

Health, 45 Center Drive, Room 3AN18A, 

Bethesda, MD 20814, (301) 435–0965, 

newmanla2@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.375, Minority Biomedical 

Research Support; 93.821, Cell Biology and 

Biophysics Research; 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.862, Genetics and 

Developmental Biology Research; 93.88, 

Minority Access to Research Careers; 93.96, 

Special Minority Initiatives; 93.859, 

Biomedical Research and Research Training, 

National Institutes of Health, HHS) 

Dated: February 12, 2021. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–03253 Filed 2–17–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Member 

Conflict: Respiratory Science. 

Date: March 11, 2021. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: Richard D Schneiderman, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4138, 

Bethesda, MD 20817, 301–402–3995, 

richard.schneiderman@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Macromolecular Structure and 

Function. 

Date: March 18–19, 2021. 

Time: 8:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: David R. Jollie, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4150, 

MSC 7806, Bethesda, MD 20892, (301) 435– 

1722, jollieda@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Medical Imaging. 

Date: March 18–19, 2021. 

Time: 9:00 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Krystyna H. Szymczyk, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 480–4198, szymczykk@

csr.nih.gov. 

Name of Committee: Molecular, Cellular 

and Developmental Neuroscience Integrated 

Review Group; Neural Oxidative Metabolism 

and Death Study Section. 

Date: March 18–19, 2021. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: Carol Hamelink, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4192, 

MSC 7850, Bethesda, MD 20892, (301) 213– 

9887 hamelinc@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; BRAIN 

Initiative: Targeted BRAIN Circuits Projects 

R01/R34. 

Date: March 18–19, 2021. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: Kirk Thompson, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5184, 

MSC 7844, Bethesda, MD 20892, 301–435– 

1242, kgt@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Health Informatics. 

Date: March 18, 2021. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: Weijia Ni, Ph.D., Chief/ 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3100, 

MSC 7808, Bethesda, MD 20892, 301–594– 

3292, niw@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Biological Chemistry, Biophysics, 

and Assay Development. 

Date: March 18, 2021. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892, (Virtual Meeting). 

Contact Person: John Harold Laity, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, 6701 Rockledge Drive, 

Bethesda, MD 20892, 301–402–8254, 

john.laity@nih.gov. 


jbell on DSKJLSW7X2PROD with NOTICES